Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Fig. 6

Apabetalone counters stimulated cytokine secretion in DM2 + CVD monocytes. a, b Secretion of proteins induced by IFNγ in DM2 + CVD monocytes is countered by 25 μM apabetalone (Apa) 24 h post-treatment (Milliplex®). c Secretion of IL-1b in DM2 + CVD monocytes was confirmed by ELISA. Statistics: 2-Way repeated measures ANOVA followed by Tukey’s multiple comparisons test; *p < 0.05; **p < 0.01; ***p < 0.001. Individual patient data were shown as a mean ± SEM

Back to article page